Introduction
============

Comparative effectiveness evidence from the Spine Patients Outcomes Research Trial showed significant improvement in patients who had surgical interventions compared to conservative treatment modalities.[@b1-jpr-5-597] However, this trial also showed a reoperation rate of 4% at 1 year and 10% at 4 years. In addition, the literature is replete with numerous evaluations illustrating a 9.5%--25% reoperation rate with a substantial proportion of patients suffering from post lumbar surgery syndrome.[@b2-jpr-5-597]--[@b11-jpr-5-597] There has been a substantial increase in surgical procedures in the US to treat low back pain. In addition to decompression surgery, spinal fusion has become a major industry in US medicine accounting for almost \$9 billion in total revenue in 2007.[@b12-jpr-5-597] It has been described that the surge in spinal fusion has occurred in a manner that is out of sync with scientific evidence regarding the risks and benefits of this form of surgery. Martin et al showed a mean reoperation rate of 6.1% at 1 year and 13.2% at 4 years, higher than the Spine Patients Outcomes Research Trial reoperation benchmarks.[@b13-jpr-5-597] Deyo et al also showed that the probability of repeat surgery at 4 years was 10.6%--17.2% in patients undergoing operations for lumbar spinal stenosis.[@b14-jpr-5-597] While there are multiple causes that require revision surgery, many causes do not require repeat surgery and may be managed by interventional techniques.[@b15-jpr-5-597]--[@b19-jpr-5-597]

The unremitting pain and disability in the low back and lower extremities following lumbar spine surgery has been hypothesized to be secondary to multiple causes including epidural fibrosis, sacroiliac joint pain, disc herniation, discogenic pain, spinal stenosis, arachnoiditis, and facet joint pain, along with inappropriate surgery.[@b7-jpr-5-597]--[@b11-jpr-5-597],[@b19-jpr-5-597],[@b20-jpr-5-597] While the debate continues on epidural fibrosis as being the major cause of pain after lumbar spine surgery with multiple authors describing lack of association,[@b21-jpr-5-597]--[@b23-jpr-5-597] Ross et al found that patients with extensive epidural fibrosis were 3.2 times more likely to experience recurrent radicular pain than those with less scarring.[@b8-jpr-5-597] In addition, experimental studies have provided electrophysiological evidence of neurologic disturbances caused by peridural scar formation.[@b24-jpr-5-597] A multitude of other abnormalities including mechanical tethering of nerve roots secondary to epidural fibrosis in the vertebral canal,[@b25-jpr-5-597],[@b26-jpr-5-597] disturbances in blood flow,[@b27-jpr-5-597] and expression of proinflammatory cytokines causing irritation of exposed dorsal root ganglion and triggering painful responses have been described.[@b28-jpr-5-597] It also has been shown that osteopontin is a major player in the formation of epidural fibrosis and a mark-up dorsal root ganglia response to peridural scar formation.[@b24-jpr-5-597] In addition, experimental evidence also has implicated paraspinal muscle spasms, tail contractures, pain behaviors, tactile allodynia, epidural and perineural scarring, and nerve root adherence to the underlying discs and pedicle in animal models.[@b29-jpr-5-597],[@b30-jpr-5-597]

Among the nonsurgical interventions in managing chronic persistent pain of post lumbar surgery syndrome, epidural steroid injections and percutaneous adhesiolysis are two of the most commonly utilized interventions.[@b15-jpr-5-597],[@b16-jpr-5-597],[@b19-jpr-5-597],[@b31-jpr-5-597]--[@b40-jpr-5-597] However, epidural steroid injections provided significant improvement in only 53% and 59% of the patients at the 12-month follow-up in a randomized double-blind controlled trial with significant improvement of 50%.[@b34-jpr-5-597] Thus, as many as 50% of patients continue to have significant pain even after fluoroscopically directed epidural injections have been utilized. Consequently, percutaneous adhesiolysis as a treatment modality in patients after the failure of conservative management including fluoroscopic epidural injections has been recommended.[@b15-jpr-5-597],[@b41-jpr-5-597],[@b42-jpr-5-597] In a recent systematic review, Helm et al assessed the available literature rigorously utilizing quality assessment and clinical relevance criteria in 15 studies, of which four randomized controlled trials and one observational study met the inclusion criteria.[@b15-jpr-5-597] They concluded that there is fair evidence that percutaneous adhesiolysis is effective in relieving low back or leg pain caused by post lumbar surgery syndrome. However, the use of epidural steroid injections and adhesiolysis have been met with skepticism, facing significant criticism in post lumbar surgery syndrome and spinal stenosis due to an alleged lack of evidence, even though supporters have described it otherwise.[@b15-jpr-5-597],[@b19-jpr-5-597],[@b34-jpr-5-597],[@b40-jpr-5-597]--[@b49-jpr-5-597] Thus, there have been multiple studies published showing the effectiveness of percutaneous adhesiolysis in recalcitrant low back pain. In fact, a 1-year follow-up of a randomized active-controlled trial evaluating percutaneous adhesiolysis and caudal epidural steroid injections in managing post lumbar surgery syndrome showed percutaneous adhesiolysis as being effective in 73% of patients at the 1-year follow-up.[@b35-jpr-5-597] This study was designed to evaluate the effectiveness of percutaneous epidural adhesiolysis in patients with chronic low back and lower extremity pain in post lumbar surgery syndrome and to compare it with fluoroscopically directed caudal epidural steroid injections. It reported the results of a 1-year follow-up.

The current report describes a 2-year follow-up of 120 patients regarding the role of percutaneous adhesiolysis in comparison to caudal epidural injections in those patients who have failed conservative management including caudal epidural injections in post lumbar surgery syndrome. The previous report of a 1-year follow-up has been published.[@b35-jpr-5-597]

Methods
=======

The study was conducted in an interventional pain management practice, a specialty referral center, in a private practice setting in the US, with the approval of the Institutional Review Board and registration of the protocol with the US Clinical Trial Registry (NCT00370994). The current study was performed based on Consolidated Standards of Reporting Trials (CONSORT) guidelines.[@b50-jpr-5-597] The study was conducted with the internal resources of the practice without external funding from industry or others.

Participants
------------

One-hundred and twenty patients were recruited from a single interventional pain management practice and were assigned to one of two groups. The Institutional Review Board-approved protocol and informed consent described in detail all aspects of the study and withdrawal process.

Group I (or control group) with 60 patients assigned received caudal epidural injections. Group II patients received percutaneous adhesiolysis in the targeted area with lidocaine, 10% sodium chloride solution, and nonparticulate betamethasone.

Preenrollment evaluation
------------------------

Preenrollment of all the patients included demographic data; medical and surgical history and coexisting disease(s); radiologic investigations; physical examination; pain rating score using the Numeric Rating Scale (NRS); functional assessment using the Oswestry Disability Index (ODI) 2.0; work status; and opioid intake.

Inclusion and exclusion criteria
--------------------------------

The first inclusion criteria was that all patients had previously undergone lumbar surgery with or without fusion at least 6 months prior to enrollment with chronic function-limiting low back pain with or without lower extremity pain of at least 6 months duration. The second criteria was that all of them had failed conservative management including, but not limited to, physical therapy, chiropractic manipulation, exercises, drug therapy, bed rest, and fluoroscopically directed caudal or transforaminal epidural injections. Additionally, only patients over the age of 18 years and patients who were able to understand the study protocol, provide voluntary written informed consent, and participate in outcome measurements were included.

Exclusion criteria included pain of facet joint origin or sacroiliac joint origin with controlled diagnostic blocks, heavy opioid use or unstable opioid use or \>400 mg morphine equivalents daily, uncontrolled psychiatric disorders, uncontrolled medical illness, and any other conditions that could interfere with the interpretation of the outcome assessments, pregnant or lactating women, and patients with a history or potential for adverse reactions to lidocaine, betamethasone, and sodium chloride solution either 0.9% or 10%.

Description of interventions
----------------------------

All procedures were performed by one physician in a sterile operating room under sterile conditions utilizing fluoroscopy and an RK needle and a Racz catheter, 19 gauge Bevi-STF (Epimed International, Farmers Branch, TX, USA). The procedure was performed with appropriate preparation, which included intravenous access, antibiotic administration, and appropriate sedation as desired.

The procedure included passage of an RK needle into the sacral hiatus and epidural space under intermittent fluoroscopy up to S3, with performance of a lumbar epidurogram utilizing approximately 5 mL of contrast with Omnipaque™ 240 (GE Healthcare, Little Chalfont, UK). In Group I, a catheter was advanced through the RK needle up to S3 and additional Omnipaque 240, 3--5 mL was injected. Following this, 5 mL of 2% preservative free Xylocaine^®^ was injected into the epidural space through the catheter.

In Group II after performing the epidurogram, a Racz catheter was passed to the area of the filling defects to the site of pathology as determined by magnetic resonance imaging, computed tomography, or symptomatology. Following the adhesiolysis, the final position was achieved in the epidural space laterally and ventrally as feasible. Following this, 3--5 mL of contrast was injected to confirm the position of the catheter along with filling of the defective area and nerve roots. If there was no subarachnoid, intravascular, or other extradural filling, and satisfactory filling was obtained with epidural and targeted nerve root filling, 5 mL of 2% preservative free Xylocaine was injected either in repeat doses of two or three or as a single dose based on whether or not the patient had a fusion.

Following the completion of the injections, the catheter was taped utilizing bioocclusive dressing in all patients.

In the recovery room, the patients were observed for any motor weakness. If no such weakness was observed and no other complications were noted after 10--15 minutes of lidocaine administration, 6 mL of normal saline in Group I or 10% sodium chloride solution in Group II were injected in two divided doses of 3 mL each. This was followed by an injection of 6 mg of nonparticulate betamethasone and flushing of the catheter with 1 mL of sodium chloride solution, followed by its removal in both groups.

Additional interventions
------------------------

Repeat percutaneous adhesiolysis procedures were provided after at least 3 months based on the response to the prior injection as evaluated by improvement in physical and functional status and also deterioration of pain relief below 50%.

All patients underwent the treatments as assigned. A patient was unblinded on request or if an emergency situation existed. If a patient required additional procedures, they were provided based on the response to the previous procedure. If the patient chose to be unblinded, they were considered as withdrawn and other treatments were provided. Patients who were nonresponsive, but continued with conservative management were followed without further procedures, but with only medical and conservative management.

Cointerventions
---------------

Patients receiving opioids and nonopioid analgesics, adjuvant analgesics, and therapeutic exercise programs continued all the interventions. There was no specific or additional intervention provided other than the study procedure. Medications were adjusted as medically necessary. All patients continued previously directed therapeutic exercise programs as well as their work, if they were working.

Objectives
----------

The objectives of this study were to evaluate the effectiveness of percutaneous adhesiolysis in managing chronic low back and/or lower extremity pain and providing effective and long-lasting pain relief with functional status improvement for patients with post lumbar surgery syndrome, and to compare the results with fluoroscopically directed caudal epidural injections.

Outcomes
--------

Various outcome measures utilized included NRS (zero to ten pain scale), ODI 2.0 (zero to 50 scale), employment status, and opioid intake in terms of daily intake or morphine equivalence. Assessments were carried out at 3, 6, 12, 18, and 24 months posttreatment. The value and validity of NRS and ODI have been reported.[@b51-jpr-5-597],[@b52-jpr-5-597]

A strong measure of improvement with significant pain relief of 50% or more and a reduced disability status with reduction of ODI scores of 50% or more was utilized as criteria for the primary outcome.[@b34-jpr-5-597],[@b36-jpr-5-597]--[@b38-jpr-5-597],[@b53-jpr-5-597]--[@b65-jpr-5-597]

The opioid intake was measured in terms of morphine equivalency.[@b66-jpr-5-597]

Employment and work status were categorized into various subgroups with those who were employable, retired, aged over 65 years, or housewife with no desire to work outside the home. However, participants who -- because of pain -- were unemployed, on sick leave, or employed but laid off were considered employable. Thus, employment statistics were based on employability.

Sample size
-----------

Sample size was calculated based on the reduction of NRS and ODI scores. A 25% clinical difference change of 1.15 (d) was set from a previous study.[@b67-jpr-5-597] With a standard deviation (σ) of the NRS of 2.3, δ = d/σ, δ = 0.50, to achieve an alpha of 0.05 and beta of 0.20 with 80% power,[@b68-jpr-5-597] 60 patients in each group of the trial were required. One-hundred patients in each group would provide 95% power (ie, alpha and beta of 0.05).

Randomization
-------------

From a total of 120 patients, 60 patients were randomly assigned into each group.

Sequence randomization
----------------------

Computer generated random allocation sequence by simple randomization was used for randomization purposes.

Allocation concealment
----------------------

The operating room nurse assisting with the procedure carried out the randomization. The nurse also prepared the drugs appropriately.

Implementation
--------------

Participants were invited to enroll in the study if they met the inclusion criteria. Inclusion was carried out by one of the three study coordinators enrolling the participants and assigning them into respective groups.

Blinding/masking
----------------

Participants and the physician administering the intervention were blinded to the group assignment. The blinding was assured by mixing the patients with other patients receiving routine treatment and not informing the physician performing the procedure of the inclusion of the patient in the study. However, blinding was considered inadequate in patients in Group I as the physician performing the procedure was informed of Group I as it was necessary to position the catheter at S3, which was not a usual practice. However, the drugs injected during the procedure were not revealed to other staff members.

Statistical methods
-------------------

Data analyses were carried out using SPSS version 9.01 (SPSS Inc, Chicago, IL). For categorical and continuous data comparison, Chi-squared statistic, Fisher's exact test, one-way analysis of variance, Student's *t*-test, and paired *t*-test were the statistical analyses used. Because the outcome measures of the participants were measured at six time points, repeated measures analysis of variance were performed with post hoc analysis. A *P-*value of less than 0.05 was considered significant.

Intent-to-treat analysis
------------------------

An intent-to-treat-analysis was performed. Either the last follow-up data or initial data were utilized in the patients who dropped out of the study or for whom no other data were available.

A sensitivity analysis with changes in the NRS was performed utilizing the last follow-up score, best case scenario, and worst case scenario. If there were no significant differences, the intention-to-treat analysis with the last follow-up visit was used.

Results
=======

[Figure 1](#f1-jpr-5-597){ref-type="fig"} illustrates the participant flow.

Recruitment
-----------

The recruitment period lasted from January 2006 to June 2010.

Baseline data
-------------

[Table 1](#t1-jpr-5-597){ref-type="table"} illustrates baseline demographic and clinical characteristics of 120 patients. All the demographic and clinical data were similar for both groups.

Therapeutic procedural characteristics
--------------------------------------

[Table 2](#t2-jpr-5-597){ref-type="table"} illustrates the therapeutic procedural characteristics with average pain relief per procedure and average number of procedures performed with back and leg pain relief described separately. Average pain relief per procedure was approximately 5 weeks in Group I, whereas it was 12 weeks in Group II -- statistically significant from Group I. The average number of procedures for 2 years was 2.4 in Group I and 6.4 in Group II. Average total relief per year was approximately 13 weeks in Group I and 40 weeks in Group II. Average total relief for 2 years was approximately 15 weeks in Group I and 78 weeks in Group II. There were significant differences with average relief and total relief.

Outcomes
--------

### Pain relief and functional assessment

[Table 3](#t3-jpr-5-597){ref-type="table"} presents the results of the repeated measures analysis. There were significant differences in pain and function between both groups, there were also significant differences from baseline to various measurement points.

### Combined pain relief and functional status

As shown in [Figure 2](#f2-jpr-5-597){ref-type="fig"}, the proportion of patients with significant reduction (greater than 50%) in NRS scores and ODI showed significant differences between both groups. This figure illustrates significant pain relief and improvement in functional status in 70% of the patients in Group II at the end of 1 year and 82% and the end of 2 years, whereas it was 5% as the end of 1 year and 2 years in the control group.

### Employment characteristics

Employment characteristics are illustrated in [Table 4](#t4-jpr-5-597){ref-type="table"}. There was no change in employment status. There were only twelve patients eligible for employment in Group I and five patients in Group II, illustrating the difficulty of postsurgery patients as the majority of them are disabled.

### Opioid intake

Opioid intake characteristics illustrate a significant decrease from the baseline; however, there were no significant differences between the groups ([Table 5](#t5-jpr-5-597){ref-type="table"}).

### Changes in weight

Changes in body weight are illustrated in [Table 6](#t6-jpr-5-597){ref-type="table"} with significant changes observed among the groups at baseline and 2-year follow-up.

### Adverse events

There were no major adverse events reported. However, there were seven subarachnoid entries in the adhesiolysis group and two patients developed postoperative weakness lasting for a few hours.

Discussion
==========

The results of the first large, randomized, active-controlled trial of the effectiveness of percutaneous adhesiolysis in comparison with caudal epidural injections in post lumbar surgery syndrome patients in managing chronic low back and/or lower extremity pain with a 2-year follow-up in 120 patients showed clinically meaningful and significant improvement in pain and functional status at the end of 1 year and 2 years in the intervention group compared to the control or caudal epidural group, in patients who have already failed conservative management and fluoroscopically directed caudal epidural injections. The results of this practical evaluation performed in a nonacademic private practice setting simulating practice patterns illustrate that in carefully selected patients not experiencing facet joint or sacroiliac joint pain, those who have failed conservative management including fluoroscopically directed caudal epidural injections showed combined pain relief and improvement in functional status in 83% of the intervention group and 5% of the control group at the end of a 2-year follow-up. Furthermore, this study also showed that patients receiving approximately six procedures over a period of 2 years experienced 78 weeks of relief, significantly different than the patients undergoing caudal epidural injections.

The results of this study illustrate the mechanism of percutaneous adhesiolysis with delivery of steroids and hypertonic sodium chloride solution to the targeted area to be superior to caudal epidural steroid injections. The defined purpose of percutaneous epidural lysis of adhesions is to eliminate the deleterious effects of scar formation, with target delivery of high concentrations of injected drugs. The postulated mechanism of epidural fibrosis as a causative factor in failed back surgery syndrome includes neurological disturbances secondary to mechanical tethering of nerve roots, disturbances in blood flow, irritation of exposed dorsal root ganglion, and nerve root adherence to the underlying discs and pedicle.[@b22-jpr-5-597]--[@b28-jpr-5-597] Adhesiolysis provides the advantage of target delivery and uninterrupted action of local anesthetics, steroids, and hypertonic sodium chloride solution. While corticosteroids have been shown to reduce inflammation by inhibiting the synthesis of a number of proinflammatory mediators,[@b69-jpr-5-597]--[@b72-jpr-5-597] local anesthetics also have been described to provide short- to long-term symptomatic relief based on various mechanisms, including separation of nociceptive discharge, block of the sympathetic reflex arc and sensitization, anti-inflammatory effect, and blockade of axonal transport of nerve fibers.[@b73-jpr-5-597]--[@b78-jpr-5-597] In addition, hypertonic sodium chloride solution has been shown to provide analgesia and neurolysis.[@b41-jpr-5-597],[@b42-jpr-5-597]

The results of this evaluation are superior to previous evaluations.[@b15-jpr-5-597],[@b79-jpr-5-597] In contrast to the previous evaluations which provided modest results, this follow-up evaluation on a long-term basis of 2 years showed 82% of the patients with significant improvement in pain and function with approximately six procedures over a period of 2 years. Even so, multiple reports have been published in favor of and against percutaneous adhesiolysis.[@b15-jpr-5-597],[@b19-jpr-5-597],[@b29-jpr-5-597],[@b40-jpr-5-597],[@b41-jpr-5-597],[@b43-jpr-5-597],[@b44-jpr-5-597],[@b46-jpr-5-597]--[@b49-jpr-5-597],[@b79-jpr-5-597] Many of the systematic reviews have been criticized for their methodology by evaluating studies inappropriately, resulting in inaccurate conclusions based on objectionable evidence synthesis.[@b15-jpr-5-597],[@b19-jpr-5-597],[@b29-jpr-5-597],[@b30-jpr-5-597],[@b36-jpr-5-597],[@b47-jpr-5-597]--[@b49-jpr-5-597] Helm et al provided a synthesis of multiple issues related to evidence assessment of percutaneous adhesiolysis.[@b15-jpr-5-597] This study may be criticized for inadequate double-blinding, lack of a placebo group, and a high proportion of patient withdrawals in the control group.

Patient blinding was considered adequate as patients were mixed together with other patients and the only occasion where blinding was not followed was in the control group, due to the placing of the catheter without adhesiolysis at S3. The chances of this confounding the results are minimal as all other personnel and patients were blinded. With interventional techniques, the design difficulties inherent in avoiding placebo and nocebo effects are a difficult venture. Present methodology appears to be the best way to provide a control group with caudal epidural injections in patients who have already failed caudal epidural injections. A new placebo design appears to have been evolving with passing the catheter subcutaneously, the feasibility and results of which need to be seen. This study with active-control with local anesthetic and steroids without adhesiolysis is considered appropriate due to the increasing influence of comparative effectiveness research in modern medicine. Furthermore, this study will provide generalizability and external validity better than a placebo-controlled trial. Placebo-control has major disadvantages. It has also been shown that the injection of inactive substances into active structures elicits various types of therapeutic or nontherapeutic effects similar to placebo and nocebo reactions.[@b80-jpr-5-597]--[@b90-jpr-5-597] However, there are numerous difficulties related to having a placebo group in interventional technique studies. Placebo experimentation continues to yield variable results. The results have shown that an injection of an inactive compound to an active structure can produce multiple types of reactions and for those methodologists who lack an understanding of placebo and nocebo in clinical trials, this may lead to confusion and the mistaken sense that they all look alike.[@b82-jpr-5-597]--[@b90-jpr-5-597] Properly controlled placebo trials have, however, shown appropriate results.

The withdrawal of a significant proportion of patients prematurely from the study is a major issue specifically for methodologists. However, in patients with chronic intractable pain providing interventions that are nonresponsive is ethically compromising. Moreover, patients cannot be expected to wait 2 years to find out if additional treatments are available for them or not. This is a practical issue related to all types of studies involving interventions specifically with placebo-control.

This is a practical clinical trial, which differs from placebo-controlled trials. In the modern era of evidence-based medicine and comparative effectiveness research, practical clinical trials are considered more appropriate than exploratory trials or efficacy trials. The differences between placebo-controlled trials and active-controlled trials include the fact that placebo-controlled trials measure absolute effect size and show the existence of effect, whereas active-controlled trials, such as the present study, not only show the existence of effect, but compare the therapies.[@b91-jpr-5-597]

In summary, the evidence in this report demonstrates that in postsurgery patients with chronic function limiting low back and/or lower extremity pain, percutaneous adhesiolysis with hypertonic sodium chloride solution injection may provide on average 78 weeks of relief over a period of 2 years with approximately six procedures per 2 years or three procedures per year.

Conclusion
==========

This study evaluated the effectiveness of percutaneous adhesiolysis in post lumbar surgery syndrome, demonstrating significant improvement in 82% of patients with pain relief and a functional status of 50% compared to the control group receiving caudal epidural injections, where improvement was seen in only 5% of patients at the 2-year follow-up.
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###### 

Demographic characteristics and clinical data

                                                   Group I (n = 60)   Group II (n = 60)   *P*-value
  ------------------------------------------------ ------------------ ------------------- -----------
  **Gender**                                                                              
  Male                                             42% (25)           42% (25)            1.00
  Female                                           58% (35)           58% (35)            
  **Age**                                                                                 
  Mean ± standard deviation                        52 ± 13.9          52 ± 12.5           0.962
  **Height (inches)**                                                                     
  Mean ± standard deviation                        67 ± 4.3           67 ± 4.0            0.807
  **Weight (lbs)**                                                                        
  Mean ± standard deviation                        185 ± 44.0         178 ± 50.1          0.458
  **Duration of pain (months)**                                                           
  Mean ± standard deviation                        186 ± 121.7        196 ± 109.4         0.642
  **Mode of onset of pain**                                                               
  Nontraumatic                                     55% (33)           57% (34)            0.540
  Traumatic                                        45% (27)           43% (26)            
  **Back pain distribution**                                                              
  Bilateral                                        72% (43)           65% (39)            0.40
  Left or right                                    28% (17)           35% (21)            
  **Leg pain distribution**                                                               
  Bilateral                                        39% (23)           35% (21)            0.926
  Left or right                                    61% (37)           65% (39)            
  **Pain ratio**                                                                          
  Back pain only                                   2% (1)             0%                  0.46
  Back worse than leg                              63% (38)           57% (34)            
  Leg worse than back                              3% (2)             8% (5)              
  Both equal                                       32% (19)           35% (21)            
  **Surgical history (number of interventions)**                                          
  One                                              50% (30)           47% (28)            0.603
  Two                                              30% (18)           23% (14)            
  Three                                            10% (6)            17% (10)            
  More than three                                  10% (6)            13% (8)             

**Note:** Unless otherwise stated, data expressed as % (n).

###### 

Therapeutic procedural characteristics with procedural frequency, average relief per procedure, and average total relief in weeks over a period of 1 year and 2 years

                                             Back pain                                                Leg pain                                                                
  ------------------------------------------ -------------------------------------------------------- -------------- -------------------------------------------------------- --------------
  Average number of procedures per year      2.2[\*](#tfn3-jpr-5-597){ref-type="table-fn"} ± 1.08     3.5 ± 1.03     2.2[\*](#tfn3-jpr-5-597){ref-type="table-fn"} ± 1.09     3.4 ± 1.03
  Average number of procedures per 2 years   2.4[\*](#tfn3-jpr-5-597){ref-type="table-fn"} ± 1.44     6.4 ± 2.35     2.4[\*](#tfn3-jpr-5-597){ref-type="table-fn"} ± 1.45     6.4 ± 2.35
  Average relief per procedure (weeks)       4.9[\*](#tfn3-jpr-5-597){ref-type="table-fn"} ± 4.00     11.7 ± 2.97    5.1[\*](#tfn3-jpr-5-597){ref-type="table-fn"} ± 3.90     11.5 ± 3.34
  Average total relief per year (weeks)      13.2[\*](#tfn3-jpr-5-597){ref-type="table-fn"} ± 14.20   40.7 ± 14.92   12.9[\*](#tfn3-jpr-5-597){ref-type="table-fn"} ± 13.71   39.7 ± 15.87
  Average total relief per 2 years (weeks)   14.8[\*](#tfn3-jpr-5-597){ref-type="table-fn"} ± 19.77   78.5 ± 32.36   15.0[\*](#tfn3-jpr-5-597){ref-type="table-fn"} ± 19.77   77.7 ± 33.07

**Note:**

Significant difference with Group II (*P* \< 0.05).

###### 

Comparison of the numeric rating scale for pain and Oswestry Disability Index score summaries at six time points

  Time points                                                           Mean ± standard deviation                                                                                                                                          
  --------------------------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------
  Baseline                                                              7.9 ± 0.8                                             8.1 ± 0.8                                             28.6 ± 4.1                                             31.2 ± 4.1
  3 months                                                              4.9[\*](#tfn5-jpr-5-597){ref-type="table-fn"} ± 1.6   3.4[\*](#tfn5-jpr-5-597){ref-type="table-fn"} ± 0.8   20.2[\*](#tfn5-jpr-5-597){ref-type="table-fn"} ± 6.6   15.2[\*](#tfn5-jpr-5-597){ref-type="table-fn"} ± 4.1
  6 months                                                              5.8[\*](#tfn5-jpr-5-597){ref-type="table-fn"} ± 1.5   3.7[\*](#tfn5-jpr-5-597){ref-type="table-fn"} ± 1.1   22.3[\*](#tfn5-jpr-5-597){ref-type="table-fn"} ± 6.1   15.2[\*](#tfn5-jpr-5-597){ref-type="table-fn"} ± 5.2
  12 months                                                             6.1[\*](#tfn5-jpr-5-597){ref-type="table-fn"} ± 1.4   4.0[\*](#tfn5-jpr-5-597){ref-type="table-fn"} ± 1.2   23.3[\*](#tfn5-jpr-5-597){ref-type="table-fn"} ± 5.8   15.8[\*](#tfn5-jpr-5-597){ref-type="table-fn"} ± 5.6
  18 months                                                             6.1[\*](#tfn5-jpr-5-597){ref-type="table-fn"} ± 1.4   3.6[\*](#tfn5-jpr-5-597){ref-type="table-fn"} ± 1.2   23.3 ± 5.7                                             14.6 ± 4.6
  24 months                                                             6.2[\*](#tfn5-jpr-5-597){ref-type="table-fn"} ± 1.4   3.6[\*](#tfn5-jpr-5-597){ref-type="table-fn"} ± 1.1   23.2 ± 6.7                                             13.9 ± 5.1
  Group difference                                                      0.001                                                 0.001                                                                                                        
  Baseline versus follow-up points                                      0.001                                                 0.001                                                                                                        
  Group by time interaction[\#](#tfn6-jpr-5-597){ref-type="table-fn"}   0.001                                                 0.001                                                                                                        

**Notes:**

Significant difference with baseline values (*P* \< 0.05);

there was significant difference between groups at 3 months, 6 months, 12 months, 18 months, and 24 months.

###### 

Employment characteristics

                              Group I   Group II                  
  --------------------------- --------- ---------- ---- ---- ---- ----
  Employment status                                               
   Employed part-time         3         3          3    1    1    1
   Employed full-time         6         6          6    4    4    4
   Unemployed                 3         3          3    0    0    0
   Total employed             9         9          9    5    5    5
  Eligible for employment     12        12         12   5    5    5
   Housewife                  4         4          4    1    1    1
   Disabled                   28        28         28   42   41   41
   \>65 years of age          16        16         16   12   13   13
   Total number of patients   60        60         60   60   60   60

**Notes:** There were no changes in Group I; one disabled became \>65 years of age in Group II.

###### 

Daily opioid (morphine equivalents)

                                                                         Group I        Group II
  ---------------------------------------------------------------------- -------------- --------------------------------------------------------
  Baseline                                                               69.6 ± 106.8   99.0 ± 117.1
  3 months                                                               68.0 ± 91.4    76.6[\*](#tfn9-jpr-5-597){ref-type="table-fn"} ± 99.8
  6 months                                                               67.9 ± 91.4    75.1[\*](#tfn9-jpr-5-597){ref-type="table-fn"} ± 97.5
  12 months                                                              67.9 ± 91.4    78.2[\*](#tfn9-jpr-5-597){ref-type="table-fn"} ± 103.7
  18 months                                                              67.9 ± 91.4    76.3[\*](#tfn9-jpr-5-597){ref-type="table-fn"} ± 96.5
  24 months                                                              67.9 ± 91.4    76.3[\*](#tfn9-jpr-5-597){ref-type="table-fn"} ± 96.5
  Group difference                                                       0.149          
  Baseline versus follow-up points                                       0.089          
  Group by time interaction[\#](#tfn10-jpr-5-597){ref-type="table-fn"}   0.485          

**Notes:**

Significant difference with baseline values (*P* \< 0.05);

there was significant difference between groups at 3 months, 6 months, 12 months, 18 months, and 24 months.

###### 

Characteristics of weight monitoring

  Weight (lbs)          n = 60         *P*-value      
  --------------------- -------------- -------------- -----------
  Weight at beginning   185.1 ± 44.0   177.6 ± 49.1   0.377
  Weight at 1 year      184.1 ± 42.8   175.9 ± 48.1   0.324
  Change                −1.0 ± 6.7     −1.7 ± 12.7    0.713
  Lost weight           33% (20)       42% (25)       
  No change             45% (27)       22% (13)       **0.021**
  Gained weight         22% (13)       37% (22)       
  Weight at 2 years     184.4 ± 42.4   176.2 ± 49.0   0.332
  Change                −0.7 ± 7.2     −1.3 ± 16.6    0.798
  Lost weight           33% (20)       45% (27)       
  No change             44% (26)       17% (10)       **0.006**
  Gained weight         23% (14)       38% (23)       

**Notes:** Data expressed as mean ± standard deviation or % (n); bold indicates significance.
